NCT06961084RecruitingPhase 2
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
Comparison of I-124 PET/CT to I-123 Whole Body Imaging for the Diagnosis of Thyroid
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- First submitted
- 29 Apr 2025
- Start date
- 4 Dec 2025
- Primary completion date
- 1 Apr 2028
- Lead sponsor
- Thomas Hope
- Diseases
- Thyroid cancer, Childhood cancers
- NCT number
- NCT06961084
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 62
- From 4 Dec 2025 to the primary completion date, 1 Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
- Known pregnancy.
Who the study is looking for
- Age \>= 13 years.
- Histopathologically confirmed differentiated or poorly differentiated thyroid cancer.
- Meeting criteria for one of the following two populations:
- American Thyroid Association (ATA) intermediate or high-risk thyroid cancer and planning on treatment using I-131.
- Metastatic disease on imaging (CT, MRI, ultrasound or FDG PET), and considering localized therapy such as surgery and radiation therapy.
- Undergone total thyroidectomy.
- Planned I-123 imaging within 45 days after enrollment.
- Ability to understand a written informed consent document, and the willingness to sign it.
Age in the registry: 13 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.